Opus Genetics Inc (IRD)

NASDAQHealth CareBiotechnologySnapshot 2026-10-23

$3.47-9.16%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Opus Genetics Inc’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-30
Revenue	—	7.54M
EPS	—	-0.085
Annual ending 2026-12-31
Revenue	—	12.21M
EPS	—	-1.031
Annual ending 2027-12-31
Revenue	—	11.94M
EPS	—	-0.704

Management figures unavailable.

What the Thesis Depends On

4 published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Manage capital allocation effectively through private placements and debt	A supporting condition in Opus Genetics Inc's published investment case. The stated target is No excessive dilution or debt beyond current levels through FY 2027.	Under Pressure	Capital raises cause >20% dilution or debt increases materially beyond current levels	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Improve earnings performance and reduce net losses	A primary condition in Opus Genetics Inc's published investment case. The stated target is Net loss improves from -$65.5M in 2026-Q1 to less negative by FY 2027.	Broken	Net losses worsen or remain flat beyond FY 2027	Net income: $-8.098M FY2026-Q2; GAAP. Published target: Net loss improves from -$65.5M in 2026-Q1 to less negative by FY 2027. Target period is not explicitly aligned with this observation. Source published Aug 6, 2026-8,098,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 91ac3b43-19a2-4e65-8dde-587ac63562de. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Secure funding to sustain operations into H2 2027	The company aims to secure funding into H2 2027.	Intact	Failure to secure funding covering operations beyond H2 2027	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Achieve and sustain revenue growth near analyst expectations	A supporting condition in Opus Genetics Inc's published investment case. The stated target is >=15% revenue growth YoY.	Improving	Revenue growth falls below 10% YoY in FY 2027	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS$-0.70

$-0.76 → $-0.70 · observed estimates

FY2027 revenue$0.01B

$0.02B → $0.01B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	$-0.76	$15,233,200	11 / 13
2026-07-25	$-0.76	$15,233,200	11 / 13
2026-07-26	$-0.76	$15,233,200	11 / 13
2026-07-27	$-0.76	$15,233,200	11 / 13
2026-07-28	$-0.76	$15,233,200	11 / 13
2026-07-29	$-0.76	$15,233,200	11 / 13
2026-07-30	$-0.76	$14,830,940	11 / 16
2026-07-31	$-0.77	$14,640,880	12 / 17
2026-08-01	$-0.76	$15,006,125	12 / 13
2026-08-02	$-0.77	$14,640,880	12 / 17
2026-08-03	$-0.77	$14,640,880	12 / 17
2026-08-04	$-0.77	$14,640,880	12 / 17
2026-08-05	$-0.77	$14,640,880	12 / 17
2026-08-06	$-0.77	$14,640,880	12 / 17
2026-08-07	$-0.75	$14,123,412	12 / 13
2026-08-08	$-0.77	$14,640,880	12 / 17
2026-08-09	$-0.77	$14,640,880	12 / 17
2026-08-10	$-0.75	$14,123,412	12 / 13
2026-08-12	$-0.75	$14,123,412	12 / 13
2026-08-13	$-0.75	$14,123,412	12 / 13
2026-08-14	$-0.75	$14,123,412	12 / 13
2026-08-15	$-0.75	$14,123,412	13 / 14
2026-08-16	$-0.75	$14,123,412	13 / 14
2026-08-17	$-0.75	$14,123,412	13 / 14
2026-08-18	$-0.75	$14,123,412	13 / 14
2026-08-19	$-0.75	$14,123,412	13 / 14
2026-08-20	$-0.70	$14,089,063	13 / 14
2026-08-21	$-0.70	$13,361,667	13 / 14
2026-08-22	$-0.70	$13,363,000	13 / 14
2026-08-23	$-0.70	$13,363,000	13 / 14
2026-08-24	$-0.70	$13,363,000	13 / 14
2026-08-25	$-0.70	$13,363,000	12 / 13
2026-08-26	$-0.70	$13,363,000	12 / 13
2026-08-27	$-0.70	$13,363,000	12 / 13
2026-08-28	$-0.70	$13,363,000	12 / 13
2026-08-29	$-0.71	$12,696,333	12 / 13
2026-08-30	$-0.71	$12,696,333	12 / 13
2026-08-31	$-0.71	$12,696,333	12 / 13
2026-09-01	$-0.71	$12,696,333	12 / 13
2026-09-02	$-0.71	$12,696,333	12 / 13
2026-09-03	$-0.71	$12,696,333	12 / 13
2026-09-04	$-0.71	$12,696,333	12 / 13
2026-09-05	$-0.71	$12,696,333	12 / 13
2026-09-06	$-0.71	$12,696,333	12 / 13
2026-09-07	$-0.71	$12,696,333	12 / 13
2026-09-08	$-0.71	$12,696,333	12 / 13
2026-09-09	$-0.71	$12,699,067	12 / 13
2026-09-10	$-0.70	$11,905,375	12 / 13
2026-09-11	$-0.70	$11,905,375	12 / 13
2026-09-12	$-0.70	$11,905,375	12 / 13
2026-09-13	$-0.70	$11,905,375	12 / 13
2026-09-14	$-0.70	$11,905,375	12 / 13
2026-09-15	$-0.70	$11,905,375	12 / 13
2026-09-16	$-0.70	$11,905,375	12 / 13
2026-09-17	$-0.70	$11,905,375	12 / 13
2026-09-18	$-0.70	$11,905,375	12 / 13
2026-09-19	$-0.70	$11,905,375	12 / 13
2026-09-20	$-0.70	$11,905,375	12 / 13
2026-09-21	$-0.70	$11,905,375	12 / 13
2026-09-22	$-0.70	$11,905,375	12 / 13
2026-09-23	$-0.70	$11,905,375	12 / 13
2026-09-24	$-0.70	$11,905,375	12 / 13
2026-09-25	$-0.70	$11,905,375	12 / 13
2026-09-26	$-0.70	$11,905,375	12 / 13
2026-09-27	$-0.70	$11,905,375	12 / 13
2026-09-28	$-0.70	$11,905,375	12 / 13
2026-09-29	$-0.70	$11,905,375	12 / 13
2026-09-30	$-0.70	$11,905,375	12 / 13
2026-10-01	$-0.70	$11,905,375	12 / 13
2026-10-02	$-0.70	$11,905,375	12 / 13
2026-10-03	$-0.70	$11,905,375	12 / 13
2026-10-04	$-0.70	$11,905,375	12 / 13
2026-10-05	$-0.70	$11,905,375	12 / 13
2026-10-06	$-0.70	$11,905,375	12 / 13
2026-10-07	$-0.70	$11,905,375	12 / 13
2026-10-08	$-0.70	$11,905,375	12 / 13
2026-10-09	$-0.70	$11,905,375	12 / 13
2026-10-10	$-0.70	$11,905,375	12 / 13
2026-10-11	$-0.70	$11,905,375	12 / 13
2026-10-12	$-0.70	$11,905,375	12 / 13
2026-10-13	$-0.70	$11,906,625	12 / 13
2026-10-14	$-0.70	$11,906,625	12 / 13
2026-10-15	$-0.70	$11,906,625	12 / 13
2026-10-16	$-0.70	$11,906,625	12 / 13
2026-10-17	$-0.70	$11,906,625	12 / 13
2026-10-18	$-0.70	$11,937,875	12 / 13
2026-10-19	$-0.70	$11,937,875	12 / 13
2026-10-20	$-0.70	$11,937,875	12 / 13
2026-10-21	$-0.70	$11,937,875	12 / 13
2026-10-22	$-0.70	$11,937,875	12 / 13
2026-10-23	$-0.70	$11,937,875	12 / 13
2026-10-24	$-0.70	$11,937,875	12 / 13

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold	Sell*
2026-05-01	16	0	0
2026-06-01	18	0	0
2026-07-01	19	0	0
2026-08-01	19	0	0
2026-09-01	19	0	0
2026-10-01	18	0	0

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 18 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades4 maintains

Recent actions · Sep 25–Oct 24 · 4 recorded

Price-target changes

30 days

Individual price-target observations are unavailable.

0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Manage capital allocation effectively through private placements and debtPublished status: Under Pressure
Improve earnings performance and reduce net lossesPublished status: Broken
Secure funding to sustain operations into H2 2027Direct metric needs a verified mapping
Achieve and sustain revenue growth near analyst expectationsDirect metric needs a verified mapping

Next proof point

Nov 11, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

4 of 4 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

2.0%Typical daily move · historical

Downside history

-49.2%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Opus Genetics Inc outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

IRD is speculative clinical-stage growth, not a proven compounder: its programs are advancing, but revenue is limited and the company is loss-making. The thesis state is watch, with the signal recently shifting from cautious to mixed; confidence in the evidence is medium.

What's priced into Opus Genetics Inc

The valuation evidence points to a premium versus peers, while the expectations gap is negative and model confidence is low. The market appears to be assigning value to future program potential, but the evidence does not show broad financial delivery; the priced-in assessment is tagged justified, with no fragility gates triggered.

What the fundamentals likely do

Near term, results may remain uneven: the company reported lower revenue and a larger operating loss in 2026-Q2, while R&D spending rose. Clinical execution has progressed, with LCA5 and BEST1 Cohort 1 enrollment completed and LCA5 dosing planned for the fourth quarter of 2026; management says resources should fund operations into 2029, though that remains an estimate.

What Opus Genetics Inc hinges on

The multi-year thesis hinges on advancing gene-therapy programs toward meaningful clinical milestones while managing cash use. Near term, a guidance cut or further weakening in jobs data could add pressure, while stronger results and guidance from healthcare bellwethers could support sector momentum.